MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13014-026-02855-4

Медицинская библиотека · Radiation oncology (London, England) · 2026

Outcome of patients with lung cancer treated with stereotactic body radiotherapy for bone oligometastases - a European multicenter cohort study.

Schäfer Sebastian, Seiler Isabell, Balermpas Panagiotis, von Wachter Camilla, Loi Mauro, Greto Daniela, Schunn Anna Sabrina, Drabke Sophia, Klischies Kenneth, Wittenstein Olaf, Willner Jochen, Lohaus Fabian, Kästner Lena, Meents Johannes, Bank Priska, Slavik Marek, Burkon Petr, Partl Richard, Müller Jörg Andreas, Dzierma Yvonne, Mader Thomas, Trommer Maike, Gkika Eleni, Rühle Alexander, Guckenberger Matthias, Moustakis Christos, Brunner Thomas, Blanck Oliver, Boda-Heggemann Judit, Nicolay Nils H, Nägler Franziska

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

INTRODUCTION

Metastasis-directed radiotherapy is of increasing importance in the multidisciplinary management of oligometastatic non-small cell lung cancer (NSCLC), but outcome patterns for stereotactic body radiotherapy (SBRT) of bone oligometastases (BoM) remain insufficiently defined. We aimed to determine oncological outcomes and prognostic factors of SBRT for BoM of NSCLC.

MATERIALS AND

METHODS

Patients with NSCLC treated with SBRT for < 5 BoM between 2010 and 2024 at 15 European cancer centers were retrospectively analyzed. Outcomes included freedom from local recurrence (FFLR), progression-free survival (PFS), overall survival (OS), and adverse events.

RESULTS

With a median follow-up of 14 months (IQR: 7-24 months), 85 patients with 111 treated BoM were analyzed. The 2-year FFLR was 87.2% (95%-CI: 73.3%-94.1%). The 1-/2-year PFS for singular BoM was 60.1% (CI: 44.6%-72.5%)/ 39.9% (CI: 24.6%-54.8%), while for 2-3 BoM they amounted to 10.2% (95%-CI: 0.6%-35.8%) and 0%. In multivariable analysis, less favorable outcome for OS and PFS was associated with larger BoM (HR 1.003; p < 0.01 and HR 1.005, p < 0.001) and increased number of treated BoM (HR 1.72; p = 0.03 and HR 1.93; p < 0.01). Treatment was well tolerated, with fracture rates of 5.4% and no grade 4 and 5 adverse events.

CONCLUSION

This multicenter cohort analysis revealed that SBRT of BoM from NSCLC appears to be an effective and well-tolerated treatment. Presence of singular BoM was a favorable prognostic factor. Prospective studies are needed to confirm these findings and to determine the role of SBRT in the multidisciplinary management of oligometastases.

Для цитирования: Schäfer Sebastian, Seiler Isabell, Balermpas Panagiotis, von Wachter Camilla, Loi Mauro, Greto Daniela, Schunn Anna Sabrina, Drabke Sophia, Klischies Kenneth, Wittenstein Olaf, Willner Jochen, Lohaus Fabian, Kästner Lena, Meents Johannes, Bank Priska, Slavik Marek, Burkon Petr, Partl Richard, Müller Jörg Andreas, Dzierma Yvonne, Mader Thomas, Trommer Maike, Gkika Eleni, Rühle Alexander, Guckenberger Matthias, Moustakis Christos, Brunner Thomas, Blanck Oliver, Boda-Heggemann Judit, Nicolay Nils H, Nägler Franziska. Outcome of patients with lung cancer treated with stereotactic body radiotherapy for bone oligometastases - a European multicenter cohort study.. Radiation oncology (London, England). 2026. DOI: 10.1186/s13014-026-02855-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.